Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the american academy of neurology

Neurology

Volumn 56, Issue 9, 2001, Pages 1143-1153

  Knopman, D S ^a   DeKosky, S T ^b   Cummings, J L ^c   Chui, H ^d   Corey Bloom, J ^e   Relkin, N ^f   Small, G W ^g   Miller, B ^h   Stevens, J C ⁱ  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Lutheran Medical Office   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMORBIDITY; CREUTZFELDT JAKOB DISEASE; CYANOCOBALAMIN DEFICIENCY; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EVIDENCE BASED MEDICINE; GENETIC ANALYSIS; HYPOTHYROIDISM; LABORATORY TEST; NEUROSYPHILIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUALITY CONTROL;

EID: 0035826782     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.9.1143     Document Type: Article

References (147)

1. Practice parameter for diagnosis and evaluation of dementia. (summary statement). Report of the quality standards subcommittee of the American Academy of Neurology
2. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
3. Standardization of the diagnosis of dementia in the Canadian study of health and aging
4. Standardization of the clinical diagnosis of the dementia syndrome and its subtypes in a cross-sectional study: The Ni-Hon-Sea experience
5. Clinical diagnosis of Alzheimer's disease and other dementias in a population survey. Agreement and causes of disagreement in applying diagnostic and statistical manual of mental disorders, revised third edition, criteria
6. Interrater agreement for diagnosis of Alzheimer's disease: The MIRAGE study
7. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease
8. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias
9. Reliability of clinical criteria for the diagnosis of dementia. A longitudinal multicenter study
10. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies
11. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: The use of NINCDS-ADRDA and DSM-III-R criteria, spect, X-ray CT, and apo E4 in medial temporal lobe dementias. Oxford project to investigate memory and aging
12. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series
13. The clinical diagnosis of Alzheimer's disease
14. Multicenter clinicopathological correlation in dementia
15. Clinical-neuropathological correlations in Alzheimer's disease and related dementias
16. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease
17. Incorrect diagnosis of Alzheimer's disease. A clinicopathologic study
18. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease
19. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype
20. A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia
21. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers
22. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
23. Multi-infarct dementia. A cause of mental deterioration in the elderly
24. Pathological verification of ischemic score in differentiation of dementias
25. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias
26. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia
27. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
28. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: A clinicopathologic study
29. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample
30. Dementia with Lewy bodies: Reliability and validity of clinical and pathologic criteria
31. Validity of clinical criteria for the diagnosis of dementia with Lewy bodies
32. Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer's disease
33. Diagnostic accuracy of dementia with Lewy bodies
34. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX
35. Simple standardised neuropsychological assessments aid in the differential diagnosis of dementia with Lewy bodies from Alzheimer's disease and vascular dementia
36. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies
37. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease
38. Frontal lobe degeneration of non-Alzheimer type revisited
39. Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia
40. A study of the Lund-Manchester research criteria for frontotemporal dementia: Clinical and single-photon emission CT correlations
41. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups
42. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
43. Frontal lobe degeneration: Clinical, neuropsychological, and SPECT characteristics
44. Cognitive and behavioral differentiation of frontal lobe degeneration of the non-Alzheimer type and Alzheimer's disease
45. Clinical and pathological evidence for a frontal variant of Alzheimer disease
46. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease
47. Creutzfeldt-Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering
48. Creutzfeldt-Jakob disease: Clinical analysis of a consecutive series of 230 neuropathologically verified cases
49. Evaluation of dementia: A systematic study of the usefulness of the American Academy of Neurology's practice parameters
50. Do surgical brain lesions present as isolated dementia? A population-based study
51. Clinical prediction rules for computed tomographic scanning in senile dementia
52. Shunting normal-pressure hydrocephalus: Do the benefits outweigh the risks? A multicenter study and literature review
53. Relationship between clinical and radiological diagnostic criteria for Alzheimer's disease and the extent of neuropathology as reflected by "stages": A prospective study
54. Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease
55. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD
56. Regional HmPAO SPECT and CT measurements in the diagnosis of Alzheimer's disease
57. MRI of the hippocampus in Alzheimer's disease: Sensitivity, specificity, and analysis of the incorrectly classified subjects
58. Hippocampus and parahippocampal gyrus linear measurements based on magnetic resonance in Alzheimer's disease
59. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
60. Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal aging, depression, vascular dementia and other causes of cognitive impairment
61. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease
62. Use of structural imaging to study the progression of Alzheimer's disease
63. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease
64. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment
65. Diagnosing Alzheimer's disease in elderly, mildly demented patients: The impact of routine single photon emission computed tomography
66. The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: A population-based study
67. Iofetamine I 123 single photon emission computed tomography is accurate in the diagnosis of Alzheimer's disease
68. Quantitative brain SPECT in Alzheimer's disease and normal aging
69. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT
70. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients
71. FDG-PET imaging in pathologically verified dementia
72. Interpretation variability of 18FDG-positron emission tomography studies in dementia
73. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia
74. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: Comparison with fluorine-18-FDG PET
75. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease
76. Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type
77. SPECT in dementia: Clinical and pathological correlation
78. A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia?
79. Cerebral glucose metabolism in patients with frontotemporal dementia
80. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands
81. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia
82. Human priori diseases
83. Basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease
84. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects
85. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
86. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
87. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF
88. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease
89. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression
90. Genotyping and cerebrospinal fluid tau protein: Implications for the clinical diagnosis of Alzheimer's disease
91. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease
92. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease
93. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
94. A sandwich enzyme immunoassay for measuring AD7C-NTP as an Alzheimer's disease marker: AD7C test
95. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid
96. Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease
97. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF
98. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies
99. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease
100. Detection of 14-3-3 protein in the CSF of genetic Creutzfeldt-Jakob disease
101. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders
102. The 14-3-3 brain protein and transmissible spongiform encephalopathy
103. 14-3-3 Protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
104. Distinction between preclinical Alzheimer's disease and depression
105. The course of geriatric depression with "reversible dementia": A controlled study
106. Depression and memory impairment: A meta-analysis of the association, its pattern, and specificity
107. Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment
108. Major depression in a population of demented and nondemented older people: Prevalence and correlates
109. Depression in patients referred to a dementia clinic. A three-year prospective study
110. The short form of the Geriatric Depression Scale: A comparison with the 30-item form
111. Screening for depression in well older adults: Evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale)
112. A rating scale for depression
113. High prevalence of cobalamin deficiency in elderly outpatients
114. Neurologic aspects of cobalamin deficiency
115. Time dependency of cognitive recovery with cobalamin replacement: Report of a pilot study
116. 12 deficiency and dementia
117. 12: Effects of replacement therapy on dementia
118. 12 deficiency on older veterans and its relationship to health
119. 12 levels and incidence of dementia in a healthy elderly population: A report from the Bronx Longitudinal Aging Study
120. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study
121. The reversible dementias: Do they reverse?
122. Reversible dementia: More than 10% or less than 1%? A quantitative review
123. Current concepts in the diagnosis of cobalamin deficiency
124. Hypothyroidism in the elderly
125. Thyroid dysfunction in adults over age 55 years. A study in an urban US community
126. Prevalence of cognitive dysfunction and hypothyroidism in an elderly community population
127. Cognitive function in non-demented older adults with hypothyroidism
128. Subclinical hypothyroidism in a biethnic, urban community
129. Association between dementia and elevated TSH: A community-based study
130. Hypothyroidism: Does treatment cure dementia?
131. Elimination of syphilis in the United States
132. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study
133. The prevalence and 3-year incidence of dementia in older black and white community residents
134. Age-specific incidence of Alzheimer's disease in a community population
135. Incidence of dementia and Alzheimer's disease: A reanalysis of data from Rochester, Minnesota, 1975-1984
136. Influence of education and occupation on the incidence of Alzheimer's disease
137. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study
138. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported
139. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state. The Kame Project
140. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans
141. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975
142. Prevalence of Alzheimer's disease in a retirement community
143. Canadian study of health and aging: Study methods and prevalence of dementia
144. A retrospective study of syphilis seropositivity in a cohort of demented patients
145. Screening for dementia and investigating its causes